YURY MALACHEVSKY: Open Payments
NPI 1326443086 · BALTIMORE, MD. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$1,490 in 90 payments from 19 companies in 2025. Trend: 2023 $1,823 · 2024 $1,996 · 2025 $1,490
Food & beverage: $1,490
| Company | Payments | Amount |
|---|---|---|
| Amgen Inc. | 15 | $237 |
| Novo Nordisk Inc | 22 | $233 |
| AstraZeneca Pharmaceuticals LP | 5 | $153 |
| Bayer Healthcare Pharmaceuticals Inc. | 7 | $150 |
| Lilly USA, LLC | 14 | $133 |
| ABBVIE INC. | 4 | $93 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | 3 | $76 |
| GlaxoSmithKline, LLC. | 3 | $69 |
| Inspire Medical Systems, Inc. | 2 | $58 |
| Astellas Pharma US Inc | 2 | $55 |
Products named: Ozempic, Kerendia, KRYSTEXXA, JARDIANCE, AIRSUPRA, Rybelsus, OTEZLA, SHINGRIX.
Industry payments across MD — which companies pay providers there.
